Why is "Aldosterone synthase" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-09 17:01:55
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Aldosterone synthase, also called steroid 18-hydroxylase, corticosterone 18-monooxygenase or P450C18, is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone and other steroids. The enzyme catalyzes sequential hydroxylations of the steroid angular methyl group at C18 after initial 11β-hydroxylation. It is encoded by the CYP11B2 gene in humans.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption - PLOS
-
Lorundrostat and Aldosterone Synthase Inhibition for Hypertension - Docwire News
-
Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism - The New England Journal of Medicine
-
Aldosterone Synthase Deficiency Type I in a Neonate: Diagnostic, Genetic, and Therapeutic Insights From a Novel CYP11B2 Variant - Cureus
-
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension - AstraZeneca
-
Journal of Internal Medicine - Wiley Online Library
-
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease - American Physiological Society Journal
-
FW In Conversation: Mineralys' CEO Jon Congleton on reviving innovation in hypertension and positioning a potential best-in-class aldosterone synthase inhibitor - FirstWord Pharma
-
Novel ASI Shows Promise for Uncontrolled Hypertension in CKD - Medscape
-
Development of Highly Selective Aldosterone Synthase Inhibitors - ACS Publications
-
Aldosterone Synthase Inhibitors Market Poised for Growth, Expected to Hit USD 369.6 Million by 2032 | Coherent Market Insights - BioSpace
-
Aldosterone synthase inhibitor offers hope for treatment of uncontrolled hypertension - News-Medical
-
Can a new class of drugs finally control hypertension in millions of patients? - statnews.com
-
Aldosterone Synthase Inhibition for Hypertension - The New England Journal of Medicine
-
AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win - Fierce Biotech
-
Baxdrostat and the future of aldosterone-targeted therapy - Nature
-
Site of action for common antihypertensive drug classes targeting the Renin-Angiotensinogen-Aldosterone pathway. - PLOS
-
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win, bolstering differentiation case - Fierce Biotech
-
Baxdrostat Lowers BP and Albuminuria in CKD with Uncontrolled Hypertension - Docwire News
-
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension - The New England Journal of Medicine
-
Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels - Nature
-
Novel Antihypertensive Effective for Uncontrolled, Resistant Hypertension - MedPage Today
-
BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension - TCTMD.com
-
AstraZeneca gears up for FDA filing after sharing details of baxdrostat's hypertension success - Fierce Biotech
-
Baxdrostat Reduces Systolic Blood Pressure in Uncontrolled, Treatment-Resistant Hypertension - Pharmacy Times
-
Aldosterone synthase deficiency due to homozygous CYP11B2 pathogenic variant with coexisting celiac disease: A case study and literature review - Termedia
-
Largest Phase III trial of novel treatment for hypertension shows promising results - Medical Xpress
-
Phase 2a Baxdrostat Data Show Promise for Primary Aldosteronism - HCPLive
-
Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN - TCTMD.com
-
Hypertension: New drug shows strong results in managing blood pressure - Medical News Today
-
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension - The New England Journal of Medicine
-
Astrazeneca Unveils Phase III Data For Baxdrostat In Resistant Hypertension - BW Healthcare World
-
FMD - New drug tackles uncontrolled hypertension caused by aldosterone dysregulation - Queen Mary University of London
-
Phase II Advance-HTN Trial Shows Lorundrostat Significantly Lowers Blood Pressure in Treatment-Resistant Hypertension - Applied Clinical Trials
-
Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review - American Heart Association Journals
-
Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2 - Fierce Biotech
-
Novel Aldosterone Synthase Inhibitor Could Enhance CKD Therapy - Renal and Urology News
-
Novel Aldosterone Synthase Inhibitor Slows CKD Progression - Renal and Urology News
-
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial - The Lancet
-
Lorundrostat Shows Continued Promise Against Uncontrolled Hypertension - Cleveland Clinic
-
Lorundrostat Lowered BP in Uncontrolled, Treatment-Resistant Hypertension - MedPage Today
-
Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results - TCTMD.com
-
Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism - Nature
-
Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators? - American Heart Association Journals
-
AHA 2024: CKD patients could benefit from an aldosterone synthase inhibitor - Clinical Trials Arena
-
Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle - TCTMD.com
-
Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors? - Nature
-
Novel agent targeting aldosterone lowers blood pressure for adults with resistant hypertension - Healio
-
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension - Frontiers
-
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension - The New England Journal of Medicine
-
AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline - AstraZeneca
-
Promising phase II results in chronic kidney disease - Boehringer Ingelheim
-
Aldosterone Synthase Inhibitors as a Therapeutic Option for Patients With Resistant Hypertension - Consultant360
-
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers - Nature
-
Novel aldosterone synthase inhibitor may aid patients with CKD - Healio
-
Aldosterone synthase inhibitor lorundrostat found to safely lower blood pressure in a clinical trial - Medical Xpress
-
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor - Patient Care Online
-
Aldosterone Synthase Structure With Cushing Disease Drug LCI699 Highlights Avenues for Selective CYP11B Drug Design - American Heart Association Journals
-
Aldosterone Synthase Inhibitor Effective for Reducing Albuminuria - HealthDay
-
Salt-dependent Blood Pressure in Human Aldosterone Synthase-Transgenic Mice - Nature
-
Lorundrostat Safely Lowers Blood Pressure in Uncontrolled Hypertension in Phase 2 Trial - Cleveland Clinic
-
FDA Clears Phase 2 Trial of Lorundrostat for Obstructive Sleep Apnea and Hypertension - Neurology Live
-
Seven years after Merck deal, ElexoPharm offloads aldosterone synthase inhibitors to Angion - Fierce Biotech
-
Baxdrostat for Treatment-Resistant Hypertension - The New England Journal of Medicine
-
Lorundrostat Stands a Chance Against Obesity-Related Hypertension - MedPage Today
-
Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression - Nature
-
Aldosterone synthase (CYP11B2) deficiency among Palestinian infants: Three novel variants and genetic heterogeneity - Wiley Online Library
-
Evaluating the role of aldosterone synthesis on adrenal cell fate - Frontiers
-
Capitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug - Fierce Biotech
-
CinCor Pharma Announces Positive Topline Data for Phase 2 - GlobeNewswire
-
CinCor Pharma Announces Topline Data for Phase 2 HALO Trial - GlobeNewswire
-
CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD - GlobeNewswire
-
Aldosterone synthase (CYP11B2) C-344T polymorphism affects the association of age-related changes of the serum C-reactive protein - Nature
-
Exciting times in treatment of resistant hypertension | InSight+ - The Medical Journal of Australia
-
Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways | Hypertension - American Heart Association Journals
-
Measured haplotype analysis of the aldosterone synthase gene and heart size - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.